Display options
Cite
Yamamoto T, Yamamura H, Yamamoto H, et al. Comparison of the efficacy of continuous i.v. infusion versus continuous regional arterial infusion of nafamostat mesylate for severe acute pancreatitis. Acute Med Surg. 2016;3(3):237-243doi: 10.1002/ams2.173.
Yamamoto, T., Yamamura, H., Yamamoto, H., & Mizobata, Y. (2016). Comparison of the efficacy of continuous i.v. infusion versus continuous regional arterial infusion of nafamostat mesylate for severe acute pancreatitis. Acute medicine & surgery, 3(3), 237-243. https://doi.org/10.1002/ams2.173
Yamamoto, Tomonori, et al. "Comparison of the efficacy of continuous i.v. infusion versus continuous regional arterial infusion of nafamostat mesylate for severe acute pancreatitis." Acute medicine & surgery vol. 3,3 (2016): 237-243. doi: https://doi.org/10.1002/ams2.173
Yamamoto T, Yamamura H, Yamamoto H, Mizobata Y. Comparison of the efficacy of continuous i.v. infusion versus continuous regional arterial infusion of nafamostat mesylate for severe acute pancreatitis. Acute Med Surg. 2016 Jan 14;3(3):237-243. doi: 10.1002/ams2.173. eCollection 2016 Jul. PMID: 29123791; PMCID: PMC5667240.
Copy Download .nbib Format: NLM
Share it on

Acute Med Surg. 2016 Jan 14;3(3):237-243. doi: 10.1002/ams2.173. eCollection 2016 Jul.

Comparison of the efficacy of continuous i.v. infusion versus continuous regional arterial infusion of nafamostat mesylate for severe acute pancreatitis.

Acute medicine & surgery

Tomonori Yamamoto, Hitoshi Yamamura, Hiromasa Yamamoto, Yasumitsu Mizobata

Affiliations

  1. Department of Trauma and Critical Care Medicine Osaka City University Osaka Japan.
  2. Department of Disaster and Critical Care Medicine Hirosaki University Osaka Japan.

PMID: 29123791 PMCID: PMC5667240 DOI: 10.1002/ams2.173

Abstract

AIM: Continuous regional arterial infusion (CRAI) of protease inhibitors may be effective in the treatment of severe acute pancreatitis (SAP), but it is more invasive than i.v. infusion. The purpose of this study was to examine the effectiveness of continuous i.v. infusion (CIVI) for SAP compared with CRAI by unifying the dose and the administration period of nafamostat mesylate.

METHODS: This study comprised 32 patients with SAP who were divided into two groups: the CRAI group and the CIVI group. The protease inhibitor, nafamostat mesylate, was continuously infused at a rate of 200 mg/day for 5 days in both groups. Clinical outcomes including in-hospital mortality were examined.

RESULTS: There were no significant between-group differences in in-hospital mortality and 90-day mortality. The duration from admission to treatment was significantly shorter in the CIVI group (median, 7 h vs. 2 h,

CONCLUSION: The effectiveness of CIVI with early nafamostat mesylate treatment after the development of SAP could be equivalent to, or better than, that of CRAI.

Keywords: Continuous intravenous infusion; continuous regional arterial infusion; nafamostat mesylate; protease inhibitor; severe acute pancreatitis

References

  1. J Clin Invest. 1986 Oct;78(4):1056-63 - PubMed
  2. JOP. 2007 Jul 09;8(4 Suppl):526-32 - PubMed
  3. Surgery. 2005 Feb;137(2):216-24 - PubMed
  4. Jpn J Pharmacol. 1986 Jun;41(2):155-62 - PubMed
  5. Pancreas. 2005 Jan;30(1):40-9 - PubMed
  6. Hepatogastroenterology. 2000 Jul-Aug;47(34):1147-50 - PubMed
  7. Crit Care Med. 2006 Mar;34(3):625-31 - PubMed
  8. Gastroenterology. 1989 Jan;96(1):193-9 - PubMed
  9. Am J Surg. 1996 Apr;171(4):394-8 - PubMed
  10. J Hepatobiliary Pancreat Sci. 2010 Jan;17 (1):37-44 - PubMed
  11. J Gastroenterol. 2013 Dec;48(12):1384-91 - PubMed
  12. Pancreas. 2010 Aug;39(6):863-7 - PubMed
  13. Transplant Proc. 2008 Jun;40(5):1310-1 - PubMed
  14. Pancreas. 2003 Apr;26(3):218-23 - PubMed
  15. Int J Pancreatol. 1992 Feb;11(1):59-65 - PubMed
  16. Pancreas. 2004 May;28(4):369-73 - PubMed
  17. J Surg Res. 1999 Dec;87(2):152-63 - PubMed

Publication Types